Roche’s divarasib was designed supply higher efficiency and selectivity to KRAS G12C in comparison with first-generation medicine on this class marketed by Amgen and Bristol Myers Squibb. The Swiss pharma firm now plans to submit the information to regulators for evaluation as a possible therapy for non-small cell lung most cancers pushed by this specific mutated protein.
The publish With New Section 3 Information, Roche Claims an Edge Over Amgen and BMS Lung Most cancers Medication appeared first on MedCity Information.
